• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1998年至2005年向美国食品药品监督管理局报告的严重药品不良事件

Serious adverse drug events reported to the Food and Drug Administration, 1998-2005.

作者信息

Moore Thomas J, Cohen Michael R, Furberg Curt D

机构信息

Institute for Safe Medication Practices, 1800 Byberry Rd, Ste 810, Huntingdon Valley, PA 19006, USA.

出版信息

Arch Intern Med. 2007 Sep 10;167(16):1752-9. doi: 10.1001/archinte.167.16.1752.

DOI:10.1001/archinte.167.16.1752
PMID:17846394
Abstract

BACKGROUND

The US Food and Drug Administration has operated the Adverse Event Reporting System since 1998. It collects all voluntary reports of adverse drug events submitted directly to the agency or through drug manufacturers.

METHODS

Using extracts published for research use, we analyzed all serious adverse drug events and medication errors in the United States reported to the Food and Drug Administration from 1998 through 2005.

RESULTS

From 1998 through 2005, reported serious adverse drug events increased 2.6-fold from 34 966 to 89 842, and fatal adverse drug events increased 2.7-fold from 5519 to 15 107. Reported serious events increased 4 times faster than the total number of outpatient prescriptions during the period. In a subset of drugs with 500 or more cases reported in any year, drugs related to safety withdrawals accounted for 26% of reported events in that group in 1999, declining to less than 1% in 2005. For 13 new biotechnology products, reported serious events grew 15.8-fold, from 580 reported in 1998 to 9181 in 2005. The increase was influenced by relatively few drugs: 298 of the 1489 drugs identified (20%) accounted for 407 394 of the 467 809 events (87%).

CONCLUSIONS

These data show a marked increase in reported deaths and serious injuries associated with drug therapy over the study period. The results highlight the importance of this public health problem and illustrate the need for improved systems to manage the risks of prescription drugs.

摘要

背景

自1998年以来,美国食品药品监督管理局一直在运作不良事件报告系统。该系统收集所有直接提交给该机构或通过药品制造商提交的药品不良事件自愿报告。

方法

利用为研究目的而发布的提取物,我们分析了1998年至2005年期间向美国食品药品监督管理局报告的美国所有严重药品不良事件和用药错误。

结果

从1998年到2005年,报告的严重药品不良事件从34966起增加到89842起,增长了2.6倍,致命药品不良事件从5519起增加到15107起,增长了2.7倍。在此期间,报告的严重事件增加速度比门诊处方总数快4倍。在每年报告病例数达到或超过500例的一部分药品中,与安全性撤市相关的药品在1999年占该组报告事件的26%,到2005年降至不到1%。对于13种新型生物技术产品,报告的严重事件增长了15.8倍,从1998年报告的580起增加到2005年的9181起。这种增长受到相对较少药品的影响:在1489种已识别药品中,有298种(20%)占467809起事件中的407394起(87%)。

结论

这些数据表明,在研究期间,与药物治疗相关的报告死亡和重伤事件显著增加。结果突出了这一公共卫生问题的重要性,并说明了改进系统以管理处方药风险的必要性。

相似文献

1
Serious adverse drug events reported to the Food and Drug Administration, 1998-2005.1998年至2005年向美国食品药品监督管理局报告的严重药品不良事件
Arch Intern Med. 2007 Sep 10;167(16):1752-9. doi: 10.1001/archinte.167.16.1752.
2
Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.1969 - 2002年美国药品不良事件监测与药物撤市:报告疑似不良反应的重要性
Arch Intern Med. 2005 Jun 27;165(12):1363-9. doi: 10.1001/archinte.165.12.1363.
3
Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.A型肉毒杆菌毒素注射:治疗和美容案例中向美国食品药品监督管理局报告的不良事件。
J Am Acad Dermatol. 2005 Sep;53(3):407-15. doi: 10.1016/j.jaad.2005.06.011.
4
Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007.儿科药物监测与美国食品药品监督管理局不良事件报告系统:2003 - 2007年报告概述
Pharmacoepidemiol Drug Saf. 2009 Jan;18(1):24-7. doi: 10.1002/pds.1679.
5
Babesia infection through blood transfusions: reports received by the US Food and Drug Administration, 1997-2007.通过输血感染巴贝斯虫:美国食品药品监督管理局收到的报告,1997 - 2007年
Clin Infect Dis. 2009 Jan 1;48(1):25-30. doi: 10.1086/595010.
6
Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).抗精神病药物、血糖紊乱与危及生命的糖尿病事件:对美国食品药品监督管理局不良事件报告系统(1968 - 2004年)的贝叶斯数据挖掘分析
Ann Clin Psychiatry. 2008 Jan-Mar;20(1):21-31. doi: 10.1080/10401230701844612.
7
Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System.局部牛凝血酶:向 FDA 的不良事件报告系统提交的局部牛凝血酶自发病例安全性报告的 21 年回顾。
Pharmacoepidemiol Drug Saf. 2010 Feb;19(2):107-14. doi: 10.1002/pds.1874.
8
Spontaneously reported fatal suspected adverse drug reactions: a 10-year survey from Sweden.自发报告的致命性可疑药物不良反应:来自瑞典的一项10年调查
Pharmacoepidemiol Drug Saf. 2007 Feb;16(2):173-80. doi: 10.1002/pds.1263.
9
Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System.向美国食品药品监督管理局的MedWatch自发报告系统报告的诺普兰使用者的严重不良事件。
Obstet Gynecol. 1995 Apr;85(4):538-42. doi: 10.1016/0029-7844(94)00457-O.
10
Development, testing, and findings of a pediatric-focused trigger tool to identify medication-related harm in US children's hospitals.一种以儿科为重点的触发工具在美国儿童医院中识别与药物相关伤害的开发、测试及结果
Pediatrics. 2008 Apr;121(4):e927-35. doi: 10.1542/peds.2007-1779.

引用本文的文献

1
Selective Serotonin Reuptake Inhibitor-Associated Intracranial Hemorrhage: Drug-Specific Risk Patterns and Patient-Level Modifiers.选择性5-羟色胺再摄取抑制剂相关性颅内出血:药物特异性风险模式及患者层面的影响因素
Neurol Int. 2025 Jul 18;17(7):111. doi: 10.3390/neurolint17070111.
2
Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II: A Review of Fatal Outcomes in US Pharmacovigilance Data and Proposed Changes.致美国食品药品监督管理局的信:提议对美国氯氮平药品说明书进行重大修改,全球氯氮平专家提供支持。第二部分:对美国药物警戒数据中致命结果的回顾及提议的修改。
J Clin Psychopharmacol. 2025;45(3):197-218. doi: 10.1097/JCP.0000000000001990. Epub 2025 Apr 9.
3
Finasteride Use: Evaluation of Depression and Suicide Risk.
非那雄胺的使用:抑郁和自杀风险评估
J Cosmet Dermatol. 2025 Mar;24(3):e70102. doi: 10.1111/jocd.70102.
4
Hepatotoxicity induced by arsenic trioxide: clinical features, mechanisms, preventive and potential therapeutic strategies.三氧化二砷所致肝毒性:临床特征、机制、预防及潜在治疗策略
Front Pharmacol. 2025 Feb 20;16:1536388. doi: 10.3389/fphar.2025.1536388. eCollection 2025.
5
A Pharmacovigilance Study on Clozapine in the Food and Drug Administration Adverse Event Reporting System: A Regional Comparative Analysis.美国食品药品监督管理局不良事件报告系统中氯氮平的药物警戒研究:区域比较分析
Clin Psychopharmacol Neurosci. 2024 Aug 31;22(3):442-450. doi: 10.9758/cpn.24.1174. Epub 2024 Jun 7.
6
Age-related differences in drug-induced liver injury: a retrospective single-center study from a large liver disease specialty hospital in China, 2002-2022.年龄相关的药物性肝损伤差异:2002-2022 年中国一家大型肝病专科医院的回顾性单中心研究。
Hepatol Int. 2024 Aug;18(4):1202-1213. doi: 10.1007/s12072-024-10679-1. Epub 2024 Jun 19.
7
Clinical and biochemical characteristics, and outcome in 33 patients with ceftriaxone-induced liver injury.33例头孢曲松所致肝损伤患者的临床和生化特征及预后
Eur J Clin Pharmacol. 2024 Sep;80(9):1317-1324. doi: 10.1007/s00228-024-03701-w. Epub 2024 May 29.
8
Cannabis oil extracts for chronic pain: what else can be learned from another structured prospective cohort?用于慢性疼痛的大麻油提取物:从另一个结构化前瞻性队列研究中还能学到什么?
Pain Rep. 2024 Apr 26;9(2):e1143. doi: 10.1097/PR9.0000000000001143. eCollection 2024 Apr.
9
Population-scale identification of differential adverse events before and during a pandemic.大流行之前和期间人群规模的差异性不良事件识别。
Nat Comput Sci. 2021 Oct;1(10):666-677. doi: 10.1038/s43588-021-00138-4. Epub 2021 Oct 5.
10
Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS).地诺单抗和唑来膦酸的适应症及不良事件概况:基于美国食品药品监督管理局不良事件报告系统(FAERS)
Front Pharmacol. 2023 Nov 1;14:1225919. doi: 10.3389/fphar.2023.1225919. eCollection 2023.